Company Culture
Life Sciences Month

Incyte CEO Hervé Hoppenot ‘motivated’ by move to downtown Wilmington

The company hopes staff will be settled in the new offices at Bracebridge by 2026, which will house all teams except R&D.

Incyte CEO Hervé Hoppenot (Technical.ly/Holly Quinn)

As Wilmington becomes a more widely acknowledged biotech hub, Incyte will have much to do with it.

The biopharmaceutical company headquartered at Augustine Cutoff, an expansion of the old Wanamaker building two miles north of downtown, started in Wilmington 24 years ago. Since then, it’s grown into a global organization with 2,600 employees in 20 countries. 

Now, it’s set to have an even bigger economic impact on the city, as it expands into three of the six Bracebridge buildings downtown. Incyte’s research and development teams will remain at the Augustine Cuttoff location, while all other departments will move to the downtown location when renovations are finished in 2026.

“’I’m very motivated by this idea of going downtown,” said Hervé Hoppenot, the chairman and CEO of Incyte. He spoke at the September DelawareBio BioBreakfast on Thursday and recently won the 2024 Pete du Pont Freedom Award for making an impact on economic growth and private sector innovation in Delaware.

The sold-out BioBreakfast drew the state’s life sciences community, as well as members of the economic development ecosystem for networking, coffee and Hoppenot’s presentation before the start of the work day. 

Incyte focuses on cancer treatments, and more recently expanded into other areas as its researchers have made unexpected discoveries. Most notably, the company has moved into the dermatology area, including recent dermatology acquisitions

Recent research and development unintentionally developed an effective treatment for the autoimmune skin discoloration disorder vitiligo, a condition that had no FDA-approved treatment at the time. Incyte’s Opzelura was FDA approved in 2019.

“It may sound a little less important than cancer, but frankly, vitiligo is a big problem for many people, and we are really committed to serving it,” Hoppenot said.  

When it comes to cancer research, Hoppenot foresees more advances from all over the world coming in the next few years. 

“Our industry has a profound geopolitical impact,” Hoppenot said. “It’s really important.” 

➡️ Read More

Companies: Incyte

Before you go...

Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.

3 ways to support our work:
  • Contribute to the Journalism Fund. Charitable giving ensures our information remains free and accessible for residents to discover workforce programs and entrepreneurship pathways. This includes philanthropic grants and individual tax-deductible donations from readers like you.
  • Use our Preferred Partners. Our directory of vetted providers offers high-quality recommendations for services our readers need, and each referral supports our journalism.
  • Use our services. If you need entrepreneurs and tech leaders to buy your services, are seeking technologists to hire or want more professionals to know about your ecosystem, Technical.ly has the biggest and most engaged audience in the mid-Atlantic. We help companies tell their stories and answer big questions to meet and serve our community.
The journalism fund Preferred partners Our services
Engagement

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!

Trending

A new model for thinking about how to grow regional economies: the Innovation Ecosystem Stack

Delaware’s next governor will be an entrepreneur. Here’s why Matt Meyer thinks it matters. 

20 tech community events in October you won’t want to miss

DelawareBio and UDel make joint hire to boost biotech innovation

Technically Media